Protection of the Heart With Doxycycline During Coronary Artery Bypass Grafting

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2009

Conditions
Coronary Artery Bypass GraftingCardiopulmonary BypassReperfusion Injury
Interventions
DRUG

Periostat

In addition to standard care, patients received oral administration of 20 mg of doxycycline twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.

DRUG

Placebo Oral Tablet

In addition to standard care, patients received oral administration of placebo twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.

Trial Locations (1)

T6G 2G3

University of Alberta Hospital, Edmonton

All Listed Sponsors
lead

University of Alberta

OTHER

NCT00246740 - Protection of the Heart With Doxycycline During Coronary Artery Bypass Grafting | Biotech Hunter | Biotech Hunter